FDA-approved medications targeting neurological conditions discussed alongside investment opportunities for companies like Supernus, Datadog, and Coinbase.
1 report, 1 independent
Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA-approved medications targeting neurological conditions discussed alongside investment opportunities for companies like Supernus, Datadog, and Coinbase.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
- FDA
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- Beren Therapeutics' medicine is under FDA review, coinciding with a CNS meeting held in Montréal, Canada.
- Both the FDA and the Drug Enforcement Administration regulate stimulant medications.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
Coverage
Newest first; wire copies grouped- StockStory2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business